133 related articles for article (PubMed ID: 31522234)
1. Validating the European randomised study for screening of prostate cancer (ERSPC) risk calculator in a contemporary South African cohort.
Kowlessur B; Phull M; Patel B; Henry M; Lazarus J
World J Urol; 2020 Jul; 38(7):1711-1718. PubMed ID: 31522234
[TBL] [Abstract][Full Text] [Related]
2. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
4. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
5. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
6. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
[TBL] [Abstract][Full Text] [Related]
7. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
8. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
9. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
[TBL] [Abstract][Full Text] [Related]
11. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
12. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer.
Borque-Fernando Á; Esteban-Escaño LM; Rubio-Briones J; Lou-Mercadé AC; García-Ruiz R; Tejero-Sánchez A; Muñoz-Rivero MV; Cabañuz-Plo T; Alfaro-Torres J; Marquina-Ibáñez IM; Hakim-Alonso S; Mejía-Urbáez E; Gil-Fabra J; Gil-Martínez P; Ávarez-Alegret R; Sanz G; Gil-Sanz MJ
Actas Urol Esp; 2016 Apr; 40(3):155-63. PubMed ID: 26598800
[TBL] [Abstract][Full Text] [Related]
13. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.
van Vugt HA; Kranse R; Steyerberg EW; van der Poel HG; Busstra M; Kil P; Oomens EH; de Jong IJ; Bangma CH; Roobol MJ
Eur J Cancer; 2012 Aug; 48(12):1809-15. PubMed ID: 22406050
[TBL] [Abstract][Full Text] [Related]
14. European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.
Gómez-Gómez E; Carrasco-Valiente J; Blanca-Pedregosa A; Barco-Sánchez B; Fernandez-Rueda JL; Molina-Abril H; Valero-Rosa J; Font-Ugalde P; Requena-Tapia MJ
Urology; 2017 Apr; 102():85-91. PubMed ID: 27840252
[TBL] [Abstract][Full Text] [Related]
15. Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
Roobol MJ; Schröder FH; Hugosson J; Jones JS; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Ankerst D; Bartsch G; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Freedland SJ; Moreira DM; Vickers AJ; Lilja H; Steyerberg EW
World J Urol; 2012 Apr; 30(2):149-55. PubMed ID: 22203238
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.
Chiu PK; Shen X; Wang G; Ho CL; Leung CH; Ng CF; Choi KS; Teoh JY
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):672-676. PubMed ID: 34267331
[TBL] [Abstract][Full Text] [Related]
17. Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
Radtke JP; Giganti F; Wiesenfarth M; Stabile A; Marenco J; Orczyk C; Kasivisvanathan V; Nyarangi-Dix JN; Schütz V; Dieffenbacher S; Görtz M; Stenzinger A; Roth W; Freeman A; Punwani S; Bonekamp D; Schlemmer HP; Hohenfellner M; Emberton M; Moore CM
PLoS One; 2019; 14(8):e0221350. PubMed ID: 31450235
[TBL] [Abstract][Full Text] [Related]
18. Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?
Lee DH; Jung HB; Park JW; Kim KH; Kim J; Lee SH; Chung BH
Yonsei Med J; 2013 May; 54(3):665-71. PubMed ID: 23549812
[TBL] [Abstract][Full Text] [Related]
19. The use of European Randomized study of Screening for Prostate Cancer calculator as a diagnostic tool for prostate biopsy indication.
Breza J; Subin F; Bernadic M; Tomas M; Pindak D
Bratisl Lek Listy; 2019; 120(5):331-335. PubMed ID: 31113194
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
